[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![Neurocrine Biosciences, Inc. Graphic](https://lunarcrush.com/gi/w:26/t:neurocrine-biosciences-inc.png) Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences presents new KINECT X post-hoc analysis demonstrating rapid and sustained therapeutic efficacy of INGREZZA. UBS raises Neurocrine Biosciences target to $195, driving positive sentiment.

### About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on treatments for neurological and endocrine-related disorders.  
Neurocrine Biosciences, Inc. uses the ticker $NBIX for trading. Listed in the [Stocks](/list/stocks) and  category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights [#](/topic/neurocrine-biosciences-inc/insights)
- Neurocrine Biosciences, Inc. (NBIX) social dominance is up XXXXXX% from the previous week.
- Neurocrine Biosciences, Inc. (NBIX) creators is up XXXXX% from the previous week.

### Price: $XXXXXX [#](/topic/neurocrine-biosciences-inc/close)
---
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/close.tsv)  
The stock price is likely to remain positive in the short term due to positive clinical trial data and strong sales, but minor downward pressure from missed EPS estimates may create some volatility. UBS raises Neurocrine Biosciences target to $195, driving positive sentiment.  

| 24-Hour | 7-Day | 30-Day |
| ------- | ----- | ------ |
| XXXX%   | XXXX% | -XXXX% |

**1-Year High**: $XXXXXX on 2025-01-30  
**1-Year Low**: $XXXXX on 2025-04-08  
  
  
### AltRank: XXXXX [#](/topic/neurocrine-biosciences-inc/alt_rank)
---
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/alt_rank.tsv)  
Neurocrine Biosciences, Inc. (NBIX) is currently AltRank #1,524 based on combined combined social and market metrics
**Daily Average**: XXX  
**1 Week**: XXX -XXX  
**1 Month**: XXXXX +1,125  
**6 Months**: XXXXX +1,101  
**1 Year**: XXXXX +780  
**1-Year High**: XXXXX on 2025-09-25  
**1-Year Low**: XX on 2025-05-06  
  
  
### Galaxy Score: XXXXX [#](/topic/neurocrine-biosciences-inc/galaxy_score)
---
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/galaxy_score.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XX  
**1 Week**: XX +2  
**1 Month**: XX -X  
**6 Months**: XX -XX  
**1 Year**: XX -XX  
**1-Year High**: XX on 2025-01-13  
**1-Year Low**: X on 2025-09-24  
  
  
### Engagements: XXXXX [#](/topic/neurocrine-biosciences-inc/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/interactions.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XXXXXX  
**1 Week**: XXXXXX -XX%  
**1 Month**: XXXXXX -XX%  
**6 Months**: XXXXXXXXX +49%  
**1 Year**: XXXXXXXXX +14%  
**1-Year High**: XXXXXXX on 2025-05-05  
**1-Year Low**: XX on 2025-10-19  

| Social Network | X     |
| -------------- | -     |
| Engagements    | XXXXX |
  

  
  
### Mentions: XX [#](/topic/neurocrine-biosciences-inc/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/posts_active.tsv)  
**Current Value**: XX  
**Daily Average**: XXX  
**1 Week**: XXX +7.30%  
**1 Month**: XXX -XX%  
**6 Months**: XXXXXX +421%  
**1 Year**: XXXXXX +388%  
**1-Year High**: XXXXX on 2025-07-03  
**1-Year Low**: XX on 2025-10-19  

| Social Network | X   |
| -------------- | -   |
| Mentions       | XXX |
  

  
  
### Creators: XX [#](/topic/neurocrine-biosciences-inc/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning Neurocrine Biosciences, Inc. (NBIX) in the last XX hours which is down XX% from XX in the previous XX hours
**Daily Average**: XXX  
**1 Week**: XX +13%  
**1 Month**: XXX -XX%  
**6 Months**: XXXXX +1,078%  
**1 Year**: XXXXXX +977%  
**1-Year High**: XXXXX on 2025-07-03  
**1-Year Low**: XX on 2025-10-19  

The most influential creators that mention Neurocrine Biosciences, Inc. in the last XX hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@Biobeats99](/creator/twitter/Biobeats99)       | X    | XXX       | X     | XXX         |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)       | X    | XXXXX     | X     | XXX         |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X    | XXXXX     | X     | XX          |
| [@Aysel32862](/creator/twitter/Aysel32862)       | X    | XXX       | X     | X           |

[View More](/list/creators/neurocrine-biosciences-inc/100)
  
  
### Sentiment: XX% [#](/topic/neurocrine-biosciences-inc/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XX% +34%  
**6 Months**: XX% +2%  
**1 Year**: XX% -X%  
**1-Year High**: XXX% on 2025-07-20  
**1-Year Low**: XX% on 2025-09-23  

**Most Supportive Themes**
- **Strong Ingrezza Sales:** (40%) Ingrezza sales are increasing market penetration and revenue.
- **Positive Clinical Trial Data:** (35%) Positive outcomes from the Crenessity Phase X study boost confidence in Neurocrine's pipeline.
- **Affordable Growth Screen:** (25%) Mentions in 'Affordable Growth' screens highlight the potential for long-term value.
  
**Most Critical Themes**
- **Missed EPS Estimates:** (5%)  Missed EPS estimates may cause short-term volatility.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXX      | XX% | XXX     | XX% | X        | X% |
|         |          |     |         |     |          |    |
| Total   | XXX      | XX% | XXX     | XX% | X        | X% |
  

  
  
### Social Dominance: XXXXXXX% [#](/topic/neurocrine-biosciences-inc/social_dominance)
---
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/social_dominance.tsv)  
**Current Value**: XXXXXXX%  
**Daily Average**: XXXXX%  
**1 Week**: XXXXXX% +0.0026%  
**1 Month**: XXXXXXX% -XXXXXXX%  
**6 Months**: XXXXXXX% -XXXX%  
**1 Year**: XXXXXXX% -XXXXXXX%  
**1-Year High**: XXXXX% on 2025-07-03  
**1-Year Low**: XXXXXX% on 2025-10-18  
  
  
### Market Dominance: XXXXX% [#](/topic/neurocrine-biosciences-inc/market_dominance)
---
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/market_dominance.tsv)  
**Current Value**: XXXXX%  
**Daily Average**: X%  
**1-Year High**: XXXXX% on 2025-04-09  
**1-Year Low**: XXXXX% on 2025-04-14  
  
  
### Market Cap: $XXXXXXXXXXXXXX [#](/topic/neurocrine-biosciences-inc/market_cap)
---
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/market_cap.tsv)  
**Current Value**: $XXXXXXXXXXXXXX  
**Daily Average**: $XXXXXXXXXXXXXX  
**1 Week**: $XXXXXXXXXXXXXX +$2.40%  
**1 Month**: $XXXXXXXXXXXXXX -$3.80%  
**6 Months**: $XXXXXXXXXXXXXX +$39%  
**1 Year**: $XXXXXXXXXXXXXX +$17%  
**1-Year High**: $XXXXXXXXXXXXXX on 2025-01-30  
**1-Year Low**: $XXXXXXXXXXXXX on 2025-04-12  

**Top assets mentioned**
In the posts about Neurocrine Biosciences, Inc. in the last XX hours

[Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix)
[BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn)
[BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio)
[Sage Therapeutics, Inc (SAGE)](/topic/$sage)
[Cytokinetics Inc. (CYTK)](/topic/$cytk)
[Karuna Therapeutics, Inc. Common Stock (KRTX)](/topic/$krtx)
[Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions)
[Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/alnylam-pharmaceuticals-inc)
[Morgan Stanley (MS)](/topic/morgan-stanley)

**Top topics mentioned**
In the posts about Neurocrine Biosciences, Inc. in the last XX hours

[stocks healthcare](/topic/stocks-healthcare), [$mngl](/topic/$mngl), [coins defi](/topic/coins-defi), [$bmrn](/topic/$bmrn), [investment](/topic/investment), [coins base ecosystem](/topic/coins-base-ecosystem), [coins dao](/topic/coins-dao), [telegram](/topic/telegram), [$642m](/topic/$642m), [$600m](/topic/$600m), [$bbio](/topic/$bbio), [stocks](/topic/stocks), [stocks technology](/topic/stocks-technology), [$sage](/topic/$sage), [$cytk](/topic/$cytk), [$krtx](/topic/$krtx), [$ions](/topic/$ions), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [alnylam pharmaceuticals inc](/topic/alnylam-pharmaceuticals-inc), [anita](/topic/anita), [morgan stanley](/topic/morgan-stanley), [$tdoc](/topic/$tdoc), [$hca](/topic/$hca), [$uhs](/topic/$uhs), [$cyh](/topic/$cyh), [$imvt](/topic/$imvt), [$bmy](/topic/$bmy), [$amgn](/topic/$amgn), [$mrna](/topic/$mrna), [$ntla](/topic/$ntla), [stocks financial services](/topic/stocks-financial-services), [$6277m](/topic/$6277m), [$1031m](/topic/$1031m), [$alny](/topic/$alny), [tesla](/topic/tesla), [advanced micro devices](/topic/advanced-micro-devices), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [$mtz](/topic/$mtz), [$mur](/topic/$mur), [$mu](/topic/$mu), [goldman sachs](/topic/goldman-sachs), [$ucb](/topic/$ucb), [$axsm](/topic/$axsm), [$acad](/topic/$acad), [$lrmr](/topic/$lrmr), [superrare](/topic/superrare), [$abbv](/topic/$abbv), [monaco](/topic/monaco), [approved](/topic/approved), [long term](/topic/long-term), [$mdgl](/topic/$mdgl), [$xene](/topic/$xene), [jpmorgan chase](/topic/jpmorgan-chase), [$mxct](/topic/$mxct), [$oii](/topic/$oii), [sarepta therapeutics inc](/topic/sarepta-therapeutics-inc), [$alxn](/topic/$alxn), [resmed inc](/topic/resmed-inc), [$rmd](/topic/$rmd), [edwards lifesciences corp](/topic/edwards-lifesciences-corp), [$ew](/topic/$ew), [$ptgx](/topic/$ptgx), [$rvmd](/topic/$rvmd), [$myok](/topic/$myok), [over the](/topic/over-the), [$abcl](/topic/$abcl), [$anab](/topic/$anab), [$arwr](/topic/$arwr), [money](/topic/money), [$dare](/topic/$dare), [coins solana ecosystem](/topic/coins-solana-ecosystem), [$prax](/topic/$prax), [$14b](/topic/$14b), [$iron](/topic/$iron), [$crsp](/topic/$crsp), [stocks bitcoin miners](/topic/stocks-bitcoin-miners), [bitcoin](/topic/bitcoin), [coins layer 1](/topic/coins-layer-1), [biogen inc](/topic/biogen-inc), [$argx](/topic/$argx), [$624m](/topic/$624m), [$255b](/topic/$255b), [exit](/topic/exit), [$insm](/topic/$insm), [$irtc](/topic/$irtc), [$ptct](/topic/$ptct), [$vctr](/topic/$vctr), [$hrmy](/topic/$hrmy), [$podd](/topic/$podd), [bank of america](/topic/bank-of-america), [united states](/topic/united-states), [$isrg](/topic/$isrg), [$isul](/topic/$isul), [etoro](/topic/etoro), [$gmab](/topic/$gmab), [$bcrx](/topic/$bcrx), [$jazz](/topic/$jazz), [$invo](/topic/$invo), [$fenc](/topic/$fenc), [$vrna](/topic/$vrna)

### Top Social Posts [#](/topic/neurocrine-biosciences-inc/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"NASDAQ - Weekend Highlights Most Active: - $TSLA / Tesla Inc - Favourable (+46 Rangebound) - $NVDA / NVIDIA Corp - Positive (+36 Rangebound) - $AMD / Advanced Micro Devices Inc - Favourable (+47 Overbought) Best Darwin Scores: - $CALM / Cal-Maine Foods Inc - Favourable (+66 Rangebound) - $LOPE / Grand Canyon Education Inc - Favourable (+65 Rangebound) - $NBIX / Neurocrine Biosciences Inc - Favourable (+50 Rangebound) Worst Darwin Scores: - $MRNA / Moderna Inc - Neutral (-42 Rangebound) - $KITT / Nauticus Robotics Inc. - Unfavourable (-40 Trending Lower) - $HTZ / Hertz Global Holdings Inc -"  
[X Link](https://x.com/Darwin_Knows/status/1979536559025402284) [@Darwin_Knows](/creator/x/Darwin_Knows) 2025-10-18T13:14Z XXX followers, XXX engagements


"Neurocrine Biosciences Presents New KINECT X Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) XX mg Capsules $NBIX"  
[X Link](https://x.com/CrweWorld/status/1979283362553696460) [@CrweWorld](/creator/x/CrweWorld) 2025-10-17T20:28Z 2280 followers, XX engagements


"$NBIX +1.56% today as Neurocrine Biosciences Presents New KINECT X Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) XX mg Capsules More Info:"  
[X Link](https://x.com/OzmosiHealth/status/1979183784164508082) [@OzmosiHealth](/creator/x/OzmosiHealth) 2025-10-17T13:52Z 2802 followers, XXX engagements


"Truist Securities: "We dont want to jinx it. but is biotech back 3Q Earnings Preview "Herein we review performance of our covered biotech companies over the course of 3Q and preview our expectations for earnings for our commercial stage companies ( $ARGX $ALNY $BBIO$BIIB $HRMY $NBIX). We also fine-tuned models ahead of the print for $ALNY and $BBIO to reflect latest Rx sales data and management commentary. After significantly increasing our 3Q Amvuttra sales projections for ALNY our PT increased to $XXX (was $459). We make no other changes to ratings or price targets. Biotech is. back The"  
[X Link](https://x.com/abhvncho/status/1979179978701877295) [@abhvncho](/creator/x/abhvncho) 2025-10-17T13:37Z XXX followers, XXX engagements